BACKGROUND:Creatine synthesis from guanidinoacetate consumes ~50% of s-adenosylmethionine (SAM)-derived methyl groups, accounting for an equivalent proportion of s-adenosylhomocysteine (SAH) and total homocysteine (tHcys) synthesis. Dietary creatine inhibits the synthesis of guanidinoacetate, thereby lowering plasma tHcys in rats. OBJECTIVE: We tested the hypotheses that creatine supplementation lowers plasma guanidinoacetate, increases blood SAM, lowers blood SAH, and lowers plasma tHcys. METHODS:Bangladeshi adults were randomly assigned to receive 1 of 4 treatments for 12 wk: placebo (n = 101), 3 g/d creatine (Cr; n = 101), 400 μg/d folic acid (FA; n = 153), or 3 g/d creatine plus 400 μg/d folic acid (Cr+FA; n = 103). The outcomes of plasma guanidinoacetate and tHcys, as well as whole blood SAM and SAH, were analyzed at baseline and week 12 by HPLC. Treatment effects of creatine supplementation were examined with the use of the group comparisons of Cr vs. placebo and Cr+FA vs. FA. RESULTS:Plasma guanidinoacetate declined by 10.6% (95% CI: 4.9, 15.9) in the Cr group while increasing nonsignificantly in the placebo group (3.7%; 95% CI: -0.8, 8.5) (Pgroup difference = 0.0002). Similarly, plasma guanidinoacetate declined by 9.0% (95% CI: 3.4, 14.2) in the Cr+FA group while increasing in the FA group (7.0%; 95% CI: 2.0, 12.2) (Pgroup difference < 0.0001). Plasma tHcys declined by 23.4% (95% CI: 19.5, 27.1) and 21.0% (95% CI: 16.4, 25.2) in the FA and Cr+FA groups, respectively (Pgroup difference = 0.41), with no significant changes in the placebo or Cr groups (Pgroup difference = 0.35). A decrease in guanidinoacetate over time was associated with a decrease in tHcys over time in the Cr+FA group (β = 0.30; 95% CI: 0.17, 0.43; P < 0.0001). CONCLUSIONS: Our findings indicate that whereas creatine supplementation downregulates endogenous creatine synthesis, this may not on average lower plasma tHcys in humans. However, tHcys did decrease in those participants who experienced a decline in plasma guanidinoacetate while receiving creatine plus folic acid supplementation. This trial was registered at clinicaltrials.gov as NCT01050556.
RCT Entities:
BACKGROUND:Creatine synthesis from guanidinoacetate consumes ~50% of s-adenosylmethionine (SAM)-derived methyl groups, accounting for an equivalent proportion of s-adenosylhomocysteine (SAH) and total homocysteine (tHcys) synthesis. Dietary creatine inhibits the synthesis of guanidinoacetate, thereby lowering plasma tHcys in rats. OBJECTIVE: We tested the hypotheses that creatine supplementation lowers plasma guanidinoacetate, increases blood SAM, lowers blood SAH, and lowers plasma tHcys. METHODS: Bangladeshi adults were randomly assigned to receive 1 of 4 treatments for 12 wk: placebo (n = 101), 3 g/d creatine (Cr; n = 101), 400 μg/d folic acid (FA; n = 153), or 3 g/d creatine plus 400 μg/d folic acid (Cr+FA; n = 103). The outcomes of plasma guanidinoacetate and tHcys, as well as whole blood SAM and SAH, were analyzed at baseline and week 12 by HPLC. Treatment effects of creatine supplementation were examined with the use of the group comparisons of Cr vs. placebo and Cr+FA vs. FA. RESULTS: Plasma guanidinoacetate declined by 10.6% (95% CI: 4.9, 15.9) in the Cr group while increasing nonsignificantly in the placebo group (3.7%; 95% CI: -0.8, 8.5) (Pgroup difference = 0.0002). Similarly, plasma guanidinoacetate declined by 9.0% (95% CI: 3.4, 14.2) in the Cr+FA group while increasing in the FA group (7.0%; 95% CI: 2.0, 12.2) (Pgroup difference < 0.0001). Plasma tHcys declined by 23.4% (95% CI: 19.5, 27.1) and 21.0% (95% CI: 16.4, 25.2) in the FA and Cr+FA groups, respectively (Pgroup difference = 0.41), with no significant changes in the placebo or Cr groups (Pgroup difference = 0.35). A decrease in guanidinoacetate over time was associated with a decrease in tHcys over time in the Cr+FA group (β = 0.30; 95% CI: 0.17, 0.43; P < 0.0001). CONCLUSIONS: Our findings indicate that whereas creatine supplementation downregulates endogenous creatine synthesis, this may not on average lower plasma tHcys in humans. However, tHcys did decrease in those participants who experienced a decline in plasma guanidinoacetate while receiving creatine plus folic acid supplementation. This trial was registered at clinicaltrials.gov as NCT01050556.
Authors: Frank Stam; Yvo M Smulders; Coen van Guldener; Cornelis Jakobs; Coen D A Stehouwer; Kees de Meer Journal: Clin Sci (Lond) Date: 2005-05 Impact factor: 6.124
Authors: Brandilyn A Peters; Megan N Hall; Xinhua Liu; Faruque Parvez; Tiffany R Sanchez; Alexander van Geen; Jacob L Mey; Abu B Siddique; Hasan Shahriar; Mohammad Nasir Uddin; Tariqul Islam; Olgica Balac; Vesna Ilievski; Pam Factor-Litvak; Joseph H Graziano; Mary V Gamble Journal: Environ Health Perspect Date: 2015-05-15 Impact factor: 9.031
Authors: Sajin Bae; Elena Kamynina; Heather M Guetterman; Adetutu F Farinola; Marie A Caudill; Robert J Berry; Patricia A Cassano; Patrick J Stover Journal: Cochrane Database Syst Rev Date: 2021-10-18
Authors: Anne K Bozack; Megan N Hall; Xinhua Liu; Vesna Ilievski; Angela M Lomax-Luu; Faruque Parvez; Abu B Siddique; Hasan Shahriar; Mohammad N Uddin; Tariqul Islam; Joseph H Graziano; Mary V Gamble Journal: Am J Clin Nutr Date: 2019-02-01 Impact factor: 7.045
Authors: Charlotte C J R Michielsen; Enrique Almanza-Aguilera; Elske M Brouwer-Brolsma; Mireia Urpi-Sarda; Lydia A Afman Journal: Genes Nutr Date: 2018-07-27 Impact factor: 5.523
Authors: Anne K Bozack; Caitlin G Howe; Megan N Hall; Xinhua Liu; Vesna Slavkovich; Vesna Ilievski; Angela M Lomax-Luu; Faruque Parvez; Abu B Siddique; Hasan Shahriar; Mohammad N Uddin; Tariqul Islam; Joseph H Graziano; Mary V Gamble Journal: Eur J Nutr Date: 2020-09-11 Impact factor: 4.865